Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Towe

Nurse Practitioner, Family Bowling Green, KY Nurse Practitioner

NPI 1861816621 CMS profile 10989352

421 US 31W Byp, Bowling Green, KY 42101

Open in the dashboard

General payments

$14,488

838 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Towe of Bowling Green, KY is reported in the CMS Open Payments database as having received $14,488 across 838 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,596 140
2024 General $3,516 196
2023 General $3,381 171
2022 General $2,629 166
2021 General $2,366 165

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Towe
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ashley Towe were reported at $2,596. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ashley Towe Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,366 $124 $35–$379 $132
2022 $2,629 $141 $44–$430 $149
2023 $3,381 $154 $49–$476 $160
2024 $3,516 $165 $51–$504 $164
2025 $2,596 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,580 236 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,407 158 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,085 67 payments
  4. Janssen Biotech, Inc. $1,067 61 payments
  5. Gilead Sciences, Inc. $872 43 payments
  6. Janssen Scientific Affairs, LLC $585 6 payments
  7. Phathom Pharmaceuticals, Inc. $505 30 payments
  8. Regeneron Healthcare Solutions, Inc. $474 16 payments
  9. QOL Medical, LLC $432 26 payments
  10. Ironwood Pharmaceuticals, Inc $377 25 payments
  11. Other $3,104 170 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,488 838 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $1,494 110 payments
  2. STELARA $1,269 47 payments
  3. RINVOQ $1,147 73 payments
  4. LINZESS $1,067 73 payments
  5. ENTYVIO $957 57 payments
  6. SKYRIZI $949 51 payments
  7. TRULANCE $913 48 payments
  8. CREON $898 64 payments
  9. MAVYRET $510 38 payments
  10. TREMFYA $469 21 payments
  11. Other $6,857 386 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,558

Median for Nurse Practitioner: 389

Drug cost

$269,935

Median for Nurse Practitioner: $21,885

Branded share of claims

40%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 123 $109,999
Xifaxan Rifaximin Brand 14 $43,804
Trulance Plecanatide Brand 41 $36,805
Motegrity Prucalopride Succinate Brand 16 $21,881
Movantik Naloxegol Oxalate Brand 28 $14,519
Dexlansoprazole Dr Dexlansoprazole Brand 27 $9,513
Sucralfate Generic 26 $5,310
Pantoprazole Sodium Generic 350 $4,772
Lubiprostone Generic 23 $4,645
Ondansetron Odt Ondansetron Brand 157 $4,036

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$111,307

Of which drugs: $81,663

Medicare patients

238

Average age 71

Services billed

18,425

136 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 37%
Ischemic heart disease 33%
Depression 30%
Heart failure 22%
COPD 20%
Chronic kidney disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ferric carboxymaltose, 1 mg J1439 Office 11 13,000 $11,287

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $192
  • GENZYME CORPORATION $150
$341 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $297
$297 14 —
STELARA
  • Janssen Biotech, Inc. $291
$291 — —
RINVOQ
  • AbbVie, Inc. $283
$283 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $264
$264 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

838 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record